0000902664-25-001007.txt : 20250214 0000902664-25-001007.hdr.sgml : 20250214 20250214143521 ACCESSION NUMBER: 0000902664-25-001007 CONFORMED SUBMISSION TYPE: SCHEDULE 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20250214 DATE AS OF CHANGE: 20250214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Applied Therapeutics, Inc. CENTRAL INDEX KEY: 0001697532 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-91017 FILM NUMBER: 25626906 BUSINESS ADDRESS: STREET 1: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-220-9226 MAIL ADDRESS: STREET 1: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: Applied Therapeutics Inc. DATE OF NAME CHANGE: 20170208 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Vestal Point Capital, LP CENTRAL INDEX KEY: 0001974915 ORGANIZATION NAME: IRS NUMBER: 922296021 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G BUSINESS ADDRESS: STREET 1: 632 BROADWAY STREET 2: SUITE 602 CITY: NEW YORK STATE: NY ZIP: 10012 BUSINESS PHONE: 6469894000 MAIL ADDRESS: STREET 1: 632 BROADWAY STREET 2: SUITE 602 CITY: NEW YORK STATE: NY ZIP: 10012 SCHEDULE 13G 1 primary_doc.xml SCHEDULE 13G 0001974915 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 12/31/2024 0001697532 Applied Therapeutics, Inc. 03828A101 545 FIFTH AVENUE, SUITE 1400 NEW YORK NY 10017 Rule 13d-1(b) Vestal Point Capital, LP DE 0.00 11500000.00 0.00 11500000.00 11500000.00 N 9.9 IA PN Ryan Wilder X1 0.00 11500000.00 0.00 11500000.00 11500000.00 N 9.9 HC IN Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 This statement is filed by: (i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Applied Therapeutics, Inc. (the "Company") directly held by the Vestal Point Fund and Account; and (ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Vestal Point Fund and Account. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012. The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 116,356,474 shares of Common Stock outstanding as of November 6, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the Securities and Exchange Commission on November 7, 2024. 9.9 The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). The Vestal Point Fund and Account has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1: Joint Filing Agreement Vestal Point Capital, LP /s/ Ryan Wilder By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner 02/14/2025 Ryan Wilder /s/ Ryan Wilder Ryan Wilder, Individually 02/14/2025 EX-99.1 2 p25-0496exhibit99_1.htm JOINT FILING AGREEMENT

EXHIBIT 99.1

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: February 14, 2025

 

 

VESTAL POINT CAPITAL, LP

By: VESTAL POINT CAPITAL, LLC,

General Partner
   
   
  By: /s/ Ryan Wilder
  Name:  Ryan Wilder
  Title:    Chief Investment Officer and Managing Partner
   
   
  /s/ Ryan Wilder
  Ryan Wilder